VELOXIS

veloxis-logo

Veloxis is a speciality pharmaceutical company focused on the development and commercialization of Envarsus® (LCP-Tacro) for the prevention of organ rejection in kidney transplant patients. Envarsus® is a once-daily dosage version of tacrolimus, the market-leading primary immunosuppressant in the transplant market, and has successfully demonstrated non-inferiority compared to Prograf® in its two Phase III clinical trials, Study 3001 (stable kidney transplant patients) and Study 3002 (de no... vo kidney transplant patients). In April 2013, the company submitted a marketing authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval to market Envarsus® for the prevention of organ rejection in kidney transplant patients in the European Union. In December 2013, the company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Envarsus® for the prevention of organ rejection in kidney transplant recipients. The submission is based on the entire data set from the company's clinical development program that comprised 25 studies and enrolled over 1000 patients, including two pivotal clinical trials, studies 3001 and 3002. At the same time, Envarsus® was granted Orphan Drug status by the FDA for prophylaxis of organ rejection in patients receiving allogenic kidney transplants. The company is using its proprietary MeltDose technology in the formulation of Envarsus® to enhance the bioavailability of the drug and allow for a sustained or modified release plasma profile. The MeltDose technology has been validated in clinical studies through FDA approval of Fenoglide (now on the market) for the treatment of dyslipidemia in adults. Veloxis was founded in June 2002 as a spin-off from H. Lundbeck A/S and is listed on NASDAQ OMX Copenhagen A/S (OMX: VELO). Veloxis is an international company with headquarters in Hørsholm, Denmark, and a fully owned subsidiary in New Jersey, U.S.

#SimilarOrganizations #People #Financial #Website #More

VELOXIS

Social Links:

Industry:
Biotechnology Health Care Medical Pharmaceutical

Founded:
2002-01-01

Address:
Hørsholm, Hovedstaden, Denmark

Country:
Denmark

Website Url:
http://www.veloxis.com

Total Employee:
11+

Status:
Active

Contact:
45 70 33 33 00

Email Addresses:
[email protected]

Total Funding:
60 M USD

Technology used in webpage:
Mobile Non Scaleable Content Amazon IPv6 Google Maps Cloudflare JS CDN JS Apache 2.4 CloudFront Ruby On Rails Token Smart App Banner


Similar Organizations

edgewise-therapeutics-logo

Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

janssen-logo

Janssen

Janssen is the pharmaceutical arm of Johnson & Johnson.

piqur-therapeutics-logo

PIQUR Therapeutics

PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.

salix-pharmaceuticals-logo

Salix Pharmaceuticals

Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.

scilex-pharmaceuticals-logo

Scilex Pharmaceuticals

Scilex Pharmaceuticals is an emerging pharmaceutical company focused on acquiring and commercializing late-stage prescription products.

vitalis-logo

Vitalis

Vitalis is a transnational pharmaceutical laboratory that engages in the development and commercialization of sterile medicines.


Current Advisors List

thomas-dyrberg_image

Thomas Dyrberg Board of Directors @ Veloxis
Board_member

mette-kirstine-agger_image

Mette Kirstine Agger Member of the Board of Directors @ Veloxis
Board_member

Current Employees Featured

tunde-otulana_image

Tunde Otulana
Tunde Otulana Chief Medical Officer @ Veloxis
Chief Medical Officer
2020-08-01

christina-sylvest_image

Christina Sylvest
Christina Sylvest SVP, Global Clinical Development & Operations @ Veloxis
SVP, Global Clinical Development & Operations

thomas-dyrberg_image

Thomas Dyrberg
Thomas Dyrberg Deputy Chairman and Director @ Veloxis
Deputy Chairman and Director
2003-09-01

craig-a-collard_image

Craig A. Collard
Craig A. Collard CEO @ Veloxis
CEO
2015-12-01

william-j-polvino_image

William J. Polvino
William J. Polvino President, CEO @ Veloxis
President, CEO

mark-hensley_image

Mark Hensley
Mark Hensley Chief Executive Officer @ Veloxis
Chief Executive Officer
2021-10-01

ira-duarte_image

Ira Duarte
Ira Duarte CFO @ Veloxis
CFO
2018-10-01

ulf-meier-kriesche_image

Ulf Meier-Kriesche
Ulf Meier-Kriesche Chief Scientific Officer @ Veloxis
Chief Scientific Officer
2017-09-01

Founder


craig-a-collard_image

Craig A. Collard

Stock Details


Company's stock symbol is CPH:VELO

Investors List

athyrium-capital-management_image

Athyrium Capital Management LP

Athyrium Capital Management LP investment in Post-IPO Debt - Veloxis

Investments List

Date Company Article Money raised
2021-09-08 Xenikos Veloxis investment in Convertible Note - Xenikos 40 M EUR

Official Site Inspections

http://www.veloxis.com Semrush global rank: 4.28 M Semrush visits lastest month: 2.69 K

  • Host name: host.zeon10.com
  • IP address: 69.16.239.108
  • Location: Lansing United States
  • Latitude: 42.7348
  • Longitude: -84.6245
  • Metro Code: 551
  • Timezone: America/Detroit
  • Postal: 48917

Loading ...

More informations about "Veloxis" on Search Engine